Nature Communications (May 2016)
A human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs
- Alexander Karlas,
- Stefano Berre,
- Thérèse Couderc,
- Margus Varjak,
- Peter Braun,
- Michael Meyer,
- Nicolas Gangneux,
- Liis Karo-Astover,
- Friderike Weege,
- Martin Raftery,
- Günther Schönrich,
- Uwe Klemm,
- Anne Wurzlbauer,
- Franz Bracher,
- Andres Merits,
- Thomas F. Meyer,
- Marc Lecuit
Affiliations
- Alexander Karlas
- Department of Molecular Biology, Max Planck Institute for Infection Biology
- Stefano Berre
- Institut Pasteur, Biology of Infection Unit
- Thérèse Couderc
- Institut Pasteur, Biology of Infection Unit
- Margus Varjak
- Institute of Technology, University of Tartu
- Peter Braun
- Department of Molecular Biology, Max Planck Institute for Infection Biology
- Michael Meyer
- Steinbeis Innovation gGmbH, Center for Systems Biomedicine
- Nicolas Gangneux
- Institut Pasteur, Biology of Infection Unit
- Liis Karo-Astover
- Institute of Technology, University of Tartu
- Friderike Weege
- Department of Molecular Biology, Max Planck Institute for Infection Biology
- Martin Raftery
- Institute of Virology, Charité University Medicine
- Günther Schönrich
- Institute of Virology, Charité University Medicine
- Uwe Klemm
- Max Planck Institute for Infection Biology, Core Facility Experimental Animals
- Anne Wurzlbauer
- Department of Pharmacy-Center for Drug Research, Ludwig-Maximilians-University
- Franz Bracher
- Department of Pharmacy-Center for Drug Research, Ludwig-Maximilians-University
- Andres Merits
- Institute of Technology, University of Tartu
- Thomas F. Meyer
- Department of Molecular Biology, Max Planck Institute for Infection Biology
- Marc Lecuit
- Institut Pasteur, Biology of Infection Unit
- DOI
- https://doi.org/10.1038/ncomms11320
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 14
Abstract
Chikungunya virus is a mosquito transmitted untreatable emergent pathogen that causes joint pain and fever. Here the authors perform a host genome-wide loss-of-function screen to identify targets for chikungunya antiviral drugs and validate hits using a mouse model of chikungunya infection.
